Interview 1652 – New World Next Week with James Evan Pilato - George Soros and Bill Gates Just Teamed Up to Buy a COVID Company
Published: July 23, 2021
Welcome to New World Next Week – the video series from Corbett Report and Media Monarchy that covers some of the most important developments in open source intelligence news. This week.
SHOW NOTES AND MP3: https://www.corbettreport.com/?p=42060
Gates Divorce, Lock down Commie, Bitcoin Salary – New World Next Week
Published: May 05, 2021
SHOW NOTES AND MP3: https://www.corbettreport.com/?p=41186 This week on the New World Next Week: the Gateses get a divorce; literal commies want to lock you down and change your behaviour; and an NFLer converts his salary to bitcoin.
The SAGE Stalinist - Why is a member of the Communist Party shaping Britain’s lock down policy?
The Minds of Men - 2018 (Official Documentary by Aaron & Melissa Dykes)
Bill Gates-Funded Company Releases Genetically Modified Mosquitoes in U.S.
A Transgenic Aedes Aegypti OX513A Mosquito, created by Oxitec in Piracicaba, Sao Paulo, Brazil, on Oct. 26, 2016
As Science Magazine put it: “flying syringes”, in order to achieve Bill and Melinda Gates and the rest of the evil elite’s objective of population reduction, culling humanity on Earth.
- By Isabel van Brugen - May 7, 2021
Genetically modified mosquitoes have been released for the first time in the United States as part of an experiment to combat insect-borne diseases such as Dengue fever, yellow fever, and the Zika virus.
UK-based biotechnology firm Oxitec, which is funded by the Bill and Melinda Gates Foundation, said it released the mosquitoes in six locations in Monroe County’s Florida Keys: two on Cudjoe Key, one on Ramrod Key, and three on Vaca Key.
It’s part of an effort to help tackle a disease-transmitting invasive mosquito population—the Aedes aegypti mosquito species—that’s responsible for “virtually all mosquito-borne diseases transmitted to humans,” according to the company.
These mosquitoes make up about 4 percent of the mosquito population in the Keys, and transmit dengue, Zika, yellow fever, and other human diseases, as well as heartworm and other potentially deadly diseases to pets and other animals.
The experiment is in collaboration with the Florida Keys Mosquito Control District (FKMCD), and was approved by the U.S. Environmental Protection Agency (EPA), the Florida Department of Agriculture and Consumer Services (FDACS), the U.S. Centers for Disease Control and Prevention, and an independent advisory board.
Over the next 12 weeks, fewer than 12,000 mosquitoes are expected to emerge each week, for approximately 12 weeks. Untreated comparison sites will be monitored with mosquito traps on Key Colony Beach, Little Torch Key, and Summerland Key.
If successful, some 20 million additional genetically modified mosquitoes will be released later in the year.
“We really started looking at this about a decade ago, because we were in the middle of a dengue fever outbreak here in the Florida Keys,” FKMCD Executive Director Andrea Leal said during a video news conference. “So we’re just very excited to move forward with this partnership, working both with Oxitec and members of the community.”
The insects released by the biotechnology firm are all male, so they don’t bite. They’re expected to mate with the local biting female mosquitoes, and in doing so, they will pass on a lethal gene that will ensure their female offspring die before reaching maturity.
According to Quartz, areas including Malaysia, Brazil, the Cayman Islands, and Panama, where similar experiments have been carried out, have seen mosquito populations drop by as much as 90 percent.
The project has faced backlash from residents, who say their consent was not sought for the experiment.
The Associated Press contributed to this report.
Are Altered Mosquitoes A Public Health Project, Or A Business?
MIT Technology Review - The fight against dengue and Zika in Latin America is turning into a contest between mosquito-altering technologies, and between profits and public health.
On Wednesday, Eliminate Dengue, a nonprofit based in Australia, said it had received $18 million from the U.S. government and other donors to rapidly launch citywide releases in Rio de Janeiro and in a suburb of Medellin, Colombia, of mosquitoes infected with a bacteria that makes the species Aedes aegypti unable to transmit the two viruses.
The scope of these Latin tests has leaped ahead of for-profit efforts by Oxitec, which has field-tested genetically modified mosquitoes in Brazil, the Cayman Islands, and Florida.
The contrasting efforts show how public health organizations, and some governments, are betting heavily on modifications that could be exceptionally cheap because they actually spread among mosquitoes as they reproduce, in effect dispersing an antidote far and wide from the point of release.
Eliminate Dengue says that by releasing females infected with the bacterium, called Wolbachia, eventually all mosquitoes in an area will acquire the germ, effectively replacing local mosquitoes with ones that don’t spread disease. It says the cost of eliminating the viruses could be as low as $1 a person, after a campaign of releasing about a million mosquitoes in a year over several square kilometers.
Companies like Oxitec, on the other hand, also aim to interrupt the spread of Zika and dengue, but they do it in smaller areas using ongoing large-scale, weekly releases of millions of sterile male mosquitoes that can’t reproduce, can’t spread their traits, and don’t stick around.
Oxitec describes its technology as “self-limiting.” The males, made sterile because of a genetic alteration, cause mosquito populations—along with the bites from females that spread disease—to decline. But it’s also likely to be more expensive. Brazilian officials working on a test with Oxitec have cited a cost of $7.50 a year, per person, to protect them from bites using Oxitec’s mosquito releases. Sterile males are often released in numbers 100 times greater than the normal males present in an area.
“The sterile male requires ongoing releases; that is why it’s associated with commercial groups, because there’s a revenue stream, like applying insecticides,” says Scott O’Neill, the entomologist who heads Eliminate Dengue, which has been funded heavily by the Bill and Melinda Gates Foundation.
Public health organizations, including the Gates Foundation, are investing in another technology able to spread on its own, called a gene drive. That is a more speculative approach, using high-tech gene-editing methods, which can cause genetic modifications to spread quickly through wild mosquitoes, potentially blocking their ability to spread disease, or causing their numbers to decline.
But Gates has invested $75 million in the idea of combating malaria, and this week the Tata Trusts of Mumbai, which controls India’s Tata industrial conglomerate, gave $70 million to the University of California, San Diego, for similar research and to train Indian scientists.
Fil Randazzo, an official with the Gates Foundation, which has already invested more than $100 million in Eliminate Dengue and its gene-drive program, Target Malaria, said in an interview earlier this year that the organization was intentionally funding self-spreading technology because it would prove cheaper to implement.
With gene drives, releasing just a few hundred mosquitoes could spread the alteration over vast areas.
“I don’t believe that there is really a business model in a self-sustaining technology for public health,” Randazzo said. “I can’t see how there would be profit in releasing a few times and then you are done.”
For companies, investing millions in technology that might be used just once doesn’t make sense. What’s more, creating permanent changes to the environment raises difficult new regulatory questions, says Hadyn Parry, CEO of Oxitec. “We work purely on our self-limiting system that does not perpetuate in the environment,” Parry said in an e-mail.
Parry said that because of the unknowns, gene drives in particular “is not an area of commercial investment.”
In addition to Oxitec, Google’s health spin-off Verily recently announced plans to use sterile male insects to fight Zika and dengue. It also uses the Wolbachia bacterium, but exploits a different property of the germ, which is that males infected with it can’t reproduce with normal females.
Nigel Snoad, who manages “Project Debug” at Verily, says the Google spin-off believes that given the scope of the Zika problem in particular, many different techniques are needed. “We think mosquito suppression has a role, and that there is a lot of room to try different things,” says Snoad.
Verily is developing automated techniques for rearing large numbers of male mosquitoes. In typical Google fashion, the company is spending heavily on scaling up the technology without a clear commercial return in view. “We don’t know yet what the business model is,” says Snoad. “That’s to be determined.”
Image citation: MIT Technology Review
Who Is Bill Gates? (Full Documentary, 2020)
Bill Gates backs project to 'dim the sun', Tucker Carlson reacts - Chemtrails Special
